In recent years,immunotherapy has made remarkable breakthroughs and brought long-term survival benefits to lung cancer patients.However,a high percentage of patients do not respond to immunotherapy or their res
In recent years, immunotherapy has made remarkable breakthroughs and brought long-term survival benefits to lung cancer patients. However, a high percentage of patients do not respond to immunotherapy or their responses are transient, indicating the existence of immune resistance. Current studies show t...
mechanisms of resistance to tumor-infiltrating lymphocyte (TIL) therapy of lung cancer. Loss of antitumor reactivity and exhaustion by infused TILs was associated with therapy resistance. New tumors that emerged lacked the original antigens or tumor-reactive T cells, which suggests adaptive resistance....
LKB1-mut has been shown as a major genetic driver of primary resistance to immune checkpoint inhibitors. Here this group reports the identification of the LKB1-IAP-JAK dynamic complex as a molecular determinant for immune response of LKB1-mut lung cancer cells. Changfa Shu , Jianfeng Li & Haian...
Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therapy. Medical management is often associated with the development of treatment resistance leading ...
lung cancer. It is well known that standard chemotherapeutic regimens have devastating effects for the patient’s immune system. Therefore, the aim of immunotherapy is to specifically enhance the immune response against the tumour. Recently, many trials addressed the role of such therapies for ...
However, a significant challenge in cancer immunotherapy is the resistance to ICI treatment, with immune tolerance playing a critical role. The mechanisms of ICI resistance are categorized into tumor-intrinsic factors and tumor-extrinsic factors [30,31,32]. Intrinsic resistance arises when tumor cells...
and promotes differentiation of CD4 T cells into Tregs and tumor cell resistance.29, 30 Both PD-L1 and PD-L2 can be expressed, not only on T cells, but also on the tumor cell surface itself and on the cells within the tumor microenvironment, allowing for direct suppression of antitumor cy...
Lung cancer is one of the primary cancer types with high incidence and mortality, and non-small cell lung cancer (NSCLC) is the most common pathological type (Molina et al.2008). With the emergence of adverse effects and the toxicity of chemotherapy drugs, the resistance of targeted therapy,...
resistance [9]. Several cancers are characterized by low concentrations of circulating tumor DNA (ctDNA), such as renal cell carcinoma, brain cancer or prostate cancer, where the application of liquid biopsy is limited [10]. At the same time, colorectal cancer (CRC), breast cancer (BC) and...